The promise of novel therapies to abolish gluten immunogenicity in celiac disease.

[1]  C. Wolf,et al.  Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease. , 2021, Gastroenterology.

[2]  K. Lundin,et al.  Frequency of Gluten-Reactive T Cells in Active Celiac Lesions Estimated by Direct Cell Cloning , 2021, Frontiers in Immunology.

[3]  Tsung-Teh Wu,et al.  TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. , 2021, Gastroenterology.

[4]  N. Ramsey,et al.  Pathogenesis of IgE‐mediated food allergy and implications for future immunotherapeutics , 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[5]  F. Koning,et al.  Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications , 2020, Gut.

[6]  M. I. Pinto-Sanchez,et al.  Current and emerging therapies for coeliac disease , 2020, Nature Reviews Gastroenterology & Hepatology.

[7]  D. Schuppan,et al.  Gluten Degrading Enzymes for Treatment of Celiac Disease , 2020, Nutrients.

[8]  Ryan M. Pearson,et al.  Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease. , 2020, Gastroenterology.

[9]  C. Khosla,et al.  IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease , 2019, Nature.

[10]  E. Macintyre,et al.  Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. , 2019, The lancet. Gastroenterology & hepatology.

[11]  M. Scheinin,et al.  Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. , 2019, The lancet. Gastroenterology & hepatology.

[12]  J. Macdougall,et al.  Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease , 2019, Alimentary pharmacology & therapeutics.

[13]  Ryan M. Pearson,et al.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[14]  Ryan M. Pearson,et al.  Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[15]  D. Sanders,et al.  Coeliac disease , 2018, The Lancet.

[16]  R. Xavier,et al.  Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. , 2017, The lancet. Gastroenterology & hepatology.

[17]  J. Murray,et al.  Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. , 2015, Gastroenterology.

[18]  H. Kiyono,et al.  Interleukin 15 and CD4⁺ T cells cooperate to promote small intestinal enteropathy in response to dietary antigen. , 2014, Gastroenterology.

[19]  D. Schuppan,et al.  Celiac disease: from pathogenesis to novel therapies. , 2009, Gastroenterology.

[20]  L. Sollid,et al.  Tissue-mediated control of immunopathology in coeliac disease , 2009, Nature Reviews Immunology.

[21]  N. Cerf-Bensussan,et al.  IL-15 Renders Conventional Lymphocytes Resistant to Suppressive Functions of Regulatory T Cells through Activation of the Phosphatidylinositol 3-Kinase Pathway1 , 2009, The Journal of Immunology.

[22]  N. Rivard,et al.  Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. , 2009, Gastroenterology.

[23]  N. Cerf-Bensussan,et al.  Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. , 2007, Gastroenterology.

[24]  A. Fasano,et al.  A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. , 2007, The American journal of clinical nutrition.